Mason Street Advisors’s Abiomed Inc ABMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-6,234
| Closed | -$2.02M | – | 1378 |
|
|
2020
Q4 | $2.02M | Sell |
6,234
-93
| -1% | -$25.7K | 0.03% | 625 |
|
|
2020
Q3 | $1.75M | Sell |
6,327
-91
| -1% | -$26.2K | 0.03% | 589 |
|
|
2020
Q2 | $1.55M | Sell |
6,418
-25
| -0.4% | -$5.02K | 0.03% | 631 |
|
|
2020
Q1 | $935K | Hold |
6,443
| – | – | 0.02% | 755 |
|
|
2019
Q4 | $1.1M | Sell |
6,443
-22
| -0.3% | -$4.08K | 0.02% | 846 |
|
|
2019
Q3 | $1.15M | Buy |
6,465
+29
| +0.5% | +$6.27K | 0.02% | 795 |
|
|
2019
Q2 | $1.68M | Buy |
6,436
+4
| +0.1% | +$1.06K | 0.04% | 646 |
|
|
2019
Q1 | $1.84M | Buy |
6,432
+82
| +1% | +$27.3K | 0.04% | 637 |
|
|
2018
Q4 | $2.06M | Buy |
6,350
+41
| +0.6% | +$14.2K | 0.05% | 450 |
|
|
2018
Q3 | $2.84M | Buy |
6,309
+381
| +6% | +$150K | 0.06% | 372 |
|
|
2018
Q2 | $2.42M | Sell |
5,928
-15,199
| -72% | -$5.51M | 0.05% | 441 |
|
|
2018
Q1 | $6.15M | Buy |
21,127
+432
| +2% | +$109K | 0.14% | 131 |
|
|
2017
Q4 | $3.88M | Sell |
20,695
-100
| -0.5% | -$18.7K | 0.09% | 230 |
|
|
2017
Q3 | $3.51M | Buy |
20,795
+888
| +4% | +$134K | 0.08% | 246 |
|
|
2017
Q2 | $2.85M | Buy |
19,907
+778
| +4% | +$105K | 0.07% | 321 |
|
|
2017
Q1 | $2.4M | Buy |
19,129
+300
| +2% | +$34.8K | 0.06% | 394 |
|
|
2016
Q4 | $2.12M | Buy |
18,829
+312
| +2% | +$36.1K | 0.06% | 426 |
|
|
2016
Q3 | $2.38M | Buy |
18,517
+587
| +3% | +$70.3K | 0.07% | 353 |
|
|
2016
Q2 | $1.96M | Buy |
17,930
+620
| +4% | +$61.7K | 0.06% | 422 |
|
|
2016
Q1 | $1.64M | Buy |
17,310
+11,020
| +175% | +$930K | 0.05% | 481 |
|
|
2015
Q4 | $568K | Buy |
6,290
+590
| +10% | +$50.1K | 0.02% | 870 |
|
|
2015
Q3 | $529K | Buy |
5,700
+511
| +10% | +$45K | 0.02% | 877 |
|
|
2015
Q2 | $341K | Buy |
5,189
+277
| +6% | +$18.4K | 0.01% | 953 |
|
|
2015
Q1 | $352K | Buy |
4,912
+177
| +4% | +$9.61K | 0.01% | 946 |
|
|
2014
Q4 | $180K | Buy |
4,735
+191
| +4% | +$6.02K | ﹤0.01% | 1527 |
|
|
2014
Q3 | $113K | Buy |
4,544
+77
| +2% | +$1.95K | ﹤0.01% | 1642 |
|
|
2014
Q2 | $112K | Buy |
4,467
+140
| +3% | +$3.26K | ﹤0.01% | 1641 |
|
|
2014
Q1 | $113K | Sell |
4,327
-1,258
| -23% | -$34.8K | ﹤0.01% | 1611 |
|
|
2013
Q4 | $149K | Buy |
5,585
+445
| +9% | +$11K | ﹤0.01% | 1602 |
|
|
2013
Q3 | $98K | Buy |
5,140
+256
| +5% | +$5.85K | ﹤0.01% | 1533 |
|
|
2013
Q2 | $105K | Buy |
+4,884
| New | +$98.2K | ﹤0.01% | 1422 |
|
Other funds holding ABMD
BCM
CS
Mason Street Advisors's ABMD Position: Q1 2021 in Review
Mason Street Advisors sold out of Abiomed Inc (ABMD) in Q1 2021, closing a stake of 6,234 shares — an estimated $2.02M sold.
Mason Street Advisors first reported a position in ABMD in Q2 2013 and held it in 31 quarters. The position peaked at $6.15M in Q1 2018. 487 funds tracked by Wall St. Rank hold ABMD as of Q1 2021.
- Mason Street Advisors reported no remaining Abiomed Inc position as of Q1 2021 after selling out during the quarter.
- Mason Street Advisors sold 6,234 Abiomed Inc shares in Q1 2021, an estimated $2.02M.
- Mason Street Advisors first reported a position in Abiomed Inc in Q2 2013 and held it in 31 quarters.
- Mason Street Advisors's Abiomed Inc position peaked at $6.15M in Q1 2018.
- 487 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2021.
Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.